comparemela.com

Latest Breaking News On - Respiratory tract diseases - Page 1 : comparemela.com

Pfizer Stock Has 29% Upside, Says a New Bull

Guggenheim analysts initiated coverage of drug firm Pfizer at Buy with a $36 price target. Shares have lagged behind the market in recent years.

Emily-dattilo
Pfizer
Courtesy-pfizer
Vamil-divan
Dow-jones-market
Wall-street
Article-normal
Pharmaceuticals
Vaccines
Textiles
Wholesalers

Moderna posts surprise quarterly profit even as COVID sales continue to slide

Moderna on Thursday reported a surprise fourth-quarter profit even as its COVID product sales continue to plunge.

Moderna-spikevax
Stephane-bancel
Centers-for-disease
Drug-administration
Merck-co
Vaccine-alliance
Moderna-inc
Chief-financial-officer-jamey-mock
Executive-stephane-bancel
Disease-control
Article-normal
Biotechnology

Moderna Stock Jumps on Surprise Profit, Sales Ahead of Expectations

Vaccine maker Moderna reported a profit of 55 cents a share on revenue of $2.8 billion in the December quarter, beating analysts’ expectations.

Jack-denton
Getty-images
Wall-street
Article-normal
Biotechnology-services
Pharmaceuticals
Vaccines
Healthcare-life-sciences
Specialized-drugs-medications
Financial-performance
Earnings

Novavax Stock Soars 26%. A Vaccine Purchase Settlement Is One Reason Why.

Novavax reaches a settlement related to an advance purchase agreement with Gavi.

John-jacobs
Angela-palumbo
Drug-administration
Getty-images
Novavax-chief-executive
Dow-jones-market
Wall-street
Article-normal
Pharmaceuticals
Vaccines
Textiles
Healthcare-life-sciences

RAPT Therapeutics stock plunges as FDA halts two clinical trials

RAPT Therapeutics shares dropped more than 60% premarket on Tuesday after the company said regulators have hit pause on two clinical trials of its.

Brian-wong
Rapt-therapeutics-inc
Drug-administration
Goldman-sachs
Article-normal
Biotechnology-services
Pharmaceuticals
Computers-consumer-electronics
Software
Applications-software
Healthcare-life-sciences
Biopharmaceuticals

vimarsana © 2020. All Rights Reserved.